CAJ | 학술논문

目的：观察DC-CIK生物免疫治疗联合放疗治疗肝癌的临床疗效。方法选取78例患者随机分为2组。2组患者均接受放射治疗，观察组在放疗的基础上联合DC-CIK生物免疫治疗。比较2组的临床治疗效果，观察患者治疗前后的免疫功能和生活质量，观察2组患者的不良反应的发生情况。结果观察组患者的治疗总有效率为80．05％，对照组为56．41％；观察组患者平均生存期为（23．8±7．4）个月，治疗组为（14．9±3．3）个月。2组患者的治疗有效率和生存期差异具有统计学意义（P＜0．05）。经过治疗后，2组患者的KPS评分较治疗前明显好转（P＜0．05）；观察组患者的免疫功能较治疗前明显好转，具有统计学意义（ P＜0．05）。治疗后观察组患者的免疫功能和KPS评分明显高于对照组（P＜0．05）。观察组5例（12．82％）患者出现不良反应，对照组4例（10．26％），差异无统计学意义（P＞0．05）。结论DC-CIK生物免疫治疗联合放疗治疗肝癌的临床疗效较为显著，患者不良反应发生率较低，值得推广应用。
목적：관찰DC-CIK생물면역치료연합방료치료간암적림상료효。방법선취78례환자수궤분위2조。2조환자균접수방사치료，관찰조재방료적기출상연합DC-CIK생물면역치료。비교2조적림상치료효과，관찰환자치료전후적면역공능화생활질량，관찰2조환자적불량반응적발생정황。결과관찰조환자적치료총유효솔위80．05％，대조조위56．41％；관찰조환자평균생존기위（23．8±7．4）개월，치료조위（14．9±3．3）개월。2조환자적치료유효솔화생존기차이구유통계학의의（P＜0．05）。경과치료후，2조환자적KPS평분교치료전명현호전（P＜0．05）；관찰조환자적면역공능교치료전명현호전，구유통계학의의（ P＜0．05）。치료후관찰조환자적면역공능화KPS평분명현고우대조조（P＜0．05）。관찰조5례（12．82％）환자출현불량반응，대조조4례（10．26％），차이무통계학의의（P＞0．05）。결론DC-CIK생물면역치료연합방료치료간암적림상료효교위현저，환자불량반응발생솔교저，치득추엄응용。
Objective To observe the clinical effect of DC-CIK immune therapy combined with radiotherapy for hepato-cellular carcinoma.Methods 78 cases of patients were randomly divided into 2 groups.All patients received radiation therapy , while the observation group was given additional DC-CIK immune therapy .Clinical effect of 2 groups were compared , immune function,quality of life and adverse reactions of the 2 groups before and after treatment of patients were observed .Results The total efficiency of the patients in the treatment group and the control group were 80.05%and 56.41%.The average survival time of patients in the observation group and the treatment group were (23.8 ±7.4) months and (14.9 ±3.3) months.The difference between effective rate and survival time of the 2 groups had statistical significance (P<0.05).After treatment,KPS score of two groups of patients significantly improved than before treatment (P<0.05),and the immune function of patients improved signifi-cantly than before treatment,with statistical significance (P<0.05).After treatment,immune function and KPS score in the ob-servation group were significantly higher than that of the control group (P<0.05).5 cases in the observation group (12.82%) had adverse reactions ,and 4 cases in the control group (10.26%) had adverse reactions ,the difference between the 2 groups had no statistical significance (P>0.05).Conclusion DC-CIK immune therapy combined with radiotherapy for hepatocellular car-cinoma has obvious clinical effect ,and incidence rate of the adverse reactions is lower .It is worthy of popularization and applica-tion.